Beijing Fengshuo Weikang Technology Development Co Ltd

1) To preliminarily evaluate the differences between the test preparation, clevidipine butyrate injection emulsion (50mL:25mg) from Beijing Shiqiao Biopharmaceutical Co., Ltd. and the reference preparation, clevidipine butyrate injection emulsion (50mL:25mg, trade name: Cleviprex®) from CHIESI USA INC; 2) To guide the formal trial design; 3) To conduct preliminary methodological validation; 4) To observe the safety of the test preparation and the reference preparation in healthy subjects.

1. Primary objectives (1) To evaluate the safety and tolerability of Pt(0506)101 for injection in patients with advanced malignant solid tumors. (2) To evaluate the pharmacokinetic characteristics of Pt(0506)101 for injection in patients with advanced malignant solid tumors after single and multiple administrations. 2. Secondary objectives (1) To preliminarily evaluate the anti-tumor efficacy of Pt(0506)101 for injection through objective indicators. (2) To provide a basis for dose selection for the Phase II clinical trial program.